Compares surgery and radiation for high-risk prostate cancer in men aged 50 to 75
Observes men with high-risk prostate cancer treated by surgery or radiation, comparing outcomes.
Key facts
- Who runs it
- Comprehensive Cancer Centre The Netherlands
- Where
- Alkmaar, Amsterdam, Assen, Beverwijk, Dordrecht, Eindhoven, Goes, Groningen, Hardenberg, Harderwijk, Hoofddorp, Hoogeveen, Hoorn, Leiden, Nijmegen, Rotterdam, Scheemda, The Hague, Tilburg, Veldhoven, and Zaandam, NetherlandsSee the 28 sites
- Trial code
- Registry title
- High-Risk prostatE Cancer radiatiOn Versus surgERy
- Status
- Recruiting
- People taking part
- 837 people, planned
- Started
- 16 Feb 2023
- Expected to end
- 30 Jun 2030
- Type of study
- Observational, 2 groups
- Record updated
- 22 May 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for men aged 50 to 75 with newly found high-risk prostate cancer that has not spread. It compares surgery with radiotherapy, with or without hormone treatment.
- Age
- 50 to 75 years
- Sex
- Men only
- Disease stage
- Newly diagnosed, high-risk prostate cancer (adenocarcinoma) that has not spread. High risk means cT3a-bN0M0, and/or ISUP grade ≥4, and/or PSA at diagnosis greater than 20 ng/mL.
- Earlier treatment
- Not stated, except that initial treatment must not include Androgen Receptor Targeted Agents (ARTA).
- Biomarker or test result
- PSA value at diagnosis greater than 20 ng/mL is one of the ways to qualify.
Main reasons for not taking part
- Cancer types other than adenocarcinoma
- Diagnosis or treatment in a hospital abroad
- Initial treatment plan with Androgen Receptor Targeted Agents (ARTA)
- Not fit for surgery or radiotherapy (WHO performance status above 1)
- Not living in the Netherlands or unable to read and understand Dutch
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Histologically confirmed de novo non-metastatic high-risk prostate cancer
- cT3a-bN0M0, according to the 8th edition of the Tumour, Node, Metastasis (TNM) classification, with the exception that clinical T-stage will be based on digital rectal examination and magnetic resonance imaging (the highest stage will be used) and/or
- International Society of Urological Pathology (ISUP) grade ≥4 and/or
- Prostate-Specific Antigen (PSA) value at diagnosis greater than 20 ng/mL
- Fit for treatment with either RARP or EBRT +/- ADT (WHO performance status 0-1)
- Living in the Netherlands
- Able to read and understand the Dutch language
Who cannot take part
- Treatment with Androgen Receptor Targeted Agents (ARTA) as part of the initial treatment plan
- Histological types other than adenocarcinoma
- Diagnosis and/or treatment in a hospital abroad
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 50 and 75 years old?
Where in Netherlands
- Noordwest ZiekenhuisgroepAlkmaar, NetherlandsContact: Berdine Heesterman, MD, PhDTaking people
- Amsterdam UMCAmsterdam, NetherlandsContact: Berdine Heesterman, MD, PhDTaking people
- Antoni van Leeuwenhoek ZiekenhuisAmsterdam, NetherlandsContact: Berdine Heesterman, MD, PhDTaking people
- BovenIJ ZiekenhuisAmsterdam, NetherlandsContact: Berdine Heesterman, MD, PhDTaking people
- OLVGAmsterdam, NetherlandsContact: Berdine Heesterman, MD, PhDTaking people
- Wilhelmina ziekenhuisAssen, NetherlandsContact: Berdine Heesterman, MD, PhDTaking people
- Rode Kruis ZiekenhuisBeverwijk, NetherlandsContact: Berdine Heesterman, MD, PhDTaking people
- Albert Schweitzer ZiekenhuisDordrecht, NetherlandsContact: Berdine Heesterman, MD, PhDTaking people
- Catharina ZiekenhuisEindhoven, NetherlandsContact: Berdine Heesterman, MD, PhDNo longer taking part
- Admiraal de Ruyter ZiekenhuisGoes, NetherlandsContact: Berdine Heesterman, MD, PhDTaking people
- Martini ZiekenhuisGroningen, NetherlandsContact: Berdine Heesterman, MD, PhDTaking people
- Universitair Medisch Centrum GroningenGroningen, NetherlandsContact: Berdine Heesterman, MD, PhDTaking people
- Saxenburgh Medisch CentrumHardenberg, NetherlandsContact: Berdine Heesterman, MD, PhDTaking people
- St.JansdalHarderwijk, NetherlandsContact: Berdine Heesterman, MD, PhDTaking people
- Spaarne GasthuisHoofddorp, NetherlandsContact: Berdine Heesterman, MD, PhDTaking people
- TreantHoogeveen, NetherlandsContact: Berdine Heesterman, MD, PhDTaking people
- Dijklander ZiekenhuisHoorn, NetherlandsContact: Berdine Heesterman, MD, PhDTaking people
- Leids Universitair Medisch CentrumLeiden, NetherlandsContact: Berdine Heesterman, MD, PhDTaking people
- Canisius Wilhelmina ZiekenhuisNijmegen, NetherlandsContact: Berdine Heesterman, MD, PhDNo longer taking part
- RadboudumcNijmegen, NetherlandsContact: Berdine Heesterman, MD, PhDNo longer taking part
- Erasmus Medisch Centrum RotterdamRotterdam, NetherlandsContact: Berdine Heesterman, MD, PhDTaking people
- Franciscus Gasthuis & VlietlandRotterdam, NetherlandsContact: Berdine Heesterman, MD, PhDTaking people
- Maasstad ZiekenhuisRotterdam, NetherlandsContact: Berdine Heesterman, MD, PhDTaking people
- Ommelander ZiekenhuisScheemda, NetherlandsContact: Berdine Heesterman, MD, PhDTaking people
- Haaglanden Medisch CentrumThe Hague, NetherlandsContact: Berdine Heesterman, MD, PhDTaking people
- Verbeeten InstituutTilburg, NetherlandsContact: Berdine Heesterman, MD, PhDTaking people
- Maxima Medisch CentrumVeldhoven, NetherlandsContact: Berdine Heesterman, MD, PhDNo longer taking part
- Zaans Medisch CentrumZaandam, NetherlandsContact: Berdine Heesterman, MD, PhDTaking people
About the trial
What the trial wants to find out
Prospective cohort study comparing robot-assisted radical prostatectomy and external beam radiotherapy +/- androgen deprivation therapy for high-risk non-metastatic prostate cancer in terms of health-related quality of life, functional outcomes, cost-effectiveness, progression-free survival and distant metastasis-free survival.
The 2 groups in the trial
- Robot assisted radical prostatectomy (RARP)
Robot-assisted radical prostatectomy, potentially as part of multimodality therapy with adjuvant radiotherapy or with (neo)adjuvant androgen deprivation therapy. Pelvic lymph node dissection (PLND) may be performed for staging purposes. The presence of positive lymph nodes (pN1) upon PLND is not a reason for exclusion and may be followed by adjuvant treatment such as lymph node irradiation.
- External beam radiotherapy (EBRT) +/- androgen deprivation therapy (ADT)
External beam radiotherapy (hypofractionated or conventionally fractionated) at a biologically effective dose converted to 2Gy fractions (α/β:1.5) of at least 76Gy. EBRT may also be combined with a brachytherapy boost and PLND may be performed for staging purposes. The presence of positive lymph nodes (pN1) upon PLND is not a reason for exclusion and lymph node irradiation may be performed.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- High-Risk prostatE Cancer radiatiOn Versus surgERy (RECOVER)
- Plain-language title
- Compares surgery and radiation for high-risk prostate cancer in men aged 50 to 75Generated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT05931419, who can take part
- Record updated
- 22 May 2026